Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
May 31, 2022
Canopy Growth (CGC, $4.88) disappoints on Q1 results

Canopy Growth (CGC, $4.88) disappoints on Q1 results

Canopy Growth announced its quarterly earnings results that missed analysts’ expectations.

The cannabis company reported ($1.46) loss per share for the quarter, missing the consensus estimate of ($0.24), Briefing.com reports. Revenue of $126.10 million, down 24.7% from the year-ago quarter, also was below  analyst estimates of $130.34 million.

Cash was at $1.4 billion as of the quarter’s end, versus $1.5 billion in long term debt. The company had a net cash position of $4 billion in 2018 but has since burned through  a lot of it.

Related Ticker: CGC

CGC in downward trend: price dove below 50-day moving average on June 02, 2026

CGC moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend. In of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CGC entered a downward trend on July 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGC's RSI Indicator exited the oversold zone, of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 77 cases where CGC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 08, 2026. You may want to consider a long position or call options on CGC as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CGC just turned positive on June 29, 2026. Looking at past instances where CGC's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.834) is normal, around the industry mean (46.335). P/E Ratio (0.000) is within average values for comparable stocks, (99.034). CGC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.679). CGC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.036). P/S Ratio (1.444) is also within normal values, averaging (114.727).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.01B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 17%. TLPH experienced the highest price growth at 36%, while BTAI experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 43%. For the same stocks of the Industry, the average monthly volume growth was 18% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 66
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
CGC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a producer of medical marijuana

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Agricultural Commodities Or Milling
Address
1 Hershey Drive
Phone
+1 855 558-9333
Employees
960
Web
https://www.canopygrowth.com
Interact to see
Advertisement
MP Materials Corp. (MP) and USA Rare Earth, Inc. (USAR) are central to the United States’ push to establish a secure, domestic supply of rare earth elements—materials critical to electric vehicles, renewable energy, and defense technologies. As geopolitical tensions and supply chain vulnerabilities intensify, these two companies offer distinct approaches to addressing U.S. dependence on foreign sources.
An AI-driven comparison between D-Wave Quantum (QBTS) and IonQ (IONQ) points to IonQ as the stronger opportunity heading into 2026. The analysis highlights IONQ’s gate-based, trapped-ion quantum architecture, which supports a wide range of algorithms and positions the company for broader adoption across AI, simulation, and cryptography.
An AI-driven comparison of Rigetti Computing (RGTI) and D-Wave Quantum (QBTS) points to Rigetti as the more compelling opportunity heading into 2026. The analysis highlights RGTI’s gate-based quantum architecture, which supports universal quantum computing and a wide range of complex algorithms. While D-Wave remains a leader in quantum annealing for optimization problems, Rigetti’s full-stack, gate-based approach offers greater scalability and broader long-term applications.
An AI-driven comparison of Rigetti Computing (RGTI) and TeraWulf (WULF) points to TeraWulf as the more attractive investment heading into 2026. The analysis emphasizes WULF’s large-scale digital infrastructure supporting Bitcoin mining and high-performance computing (HPC), which generates immediate revenue in expanding digital asset and AI-driven markets.
An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure.
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.
An AI-driven comparison of UnitedHealth Group (UNH) and CVS Health (CVS) points to UnitedHealth as the stronger investment heading into 2026. The analysis emphasizes UNH’s deeply integrated healthcare model, combining insurance, data analytics, pharmacy services, and care delivery into a single ecosystem. This structure provides resilience and earnings stability in an increasingly complex healthcare environment.
An AI-driven comparison of Coca-Cola (KO) and PepsiCo (PEP) points to PepsiCo as the more compelling investment for 2026. The analysis emphasizes PepsiCo’s diversified business model, which combines beverages with a broad snack portfolio and provides greater resilience as consumer preferences evolve.
SoundThinking, Inc. (SSTI), a developer of precision-policing and security technologies, has faced a difficult trading environment in recent weeks. With shares trading in the single digits, the stock reflects broader investor hesitation toward small-cap tech amid ongoing economic uncertainty. The company’s market capitalization stands near $100 million, and its valuation metrics suggest skepticism around its growth outlook.
Lionheart Holdings (CUB) has traded quietly in recent sessions, reflecting the typical behavior of a SPAC still in its pre-merger search phase. Shares have hovered close to the company’s IPO price, supported by low volatility and thin trading volumes. This pattern mirrors broader trends across the SPAC market, where investor engagement often remains subdued until a definitive acquisition agreement is announced.
Astronics Corporation has delivered solid share price performance in recent sessions, benefiting from renewed enthusiasm for aerospace and defense equities. The stock has demonstrated resilience despite broader market volatility, drawing consistent investor interest due to its exposure to mission-critical avionics, power systems, and test equipment.
Recent analyst upgrades from Piper Sandler and Morgan Stanley underscore improving valuation and renewed confidence in Motorola Solutions’ growth outlook. Third-quarter 2025 results exceeded expectations, with revenue increasing 7.8% year over year, driven by land mobile radio (LMR) and video security demand.
General Dynamics shares have remained resilient in recent sessions, continuing an upward trend despite broader market volatility. Heightened attention on global defense spending has reinforced confidence in the company’s extensive backlog and well-balanced exposure across aerospace, marine systems, combat platforms, and mission-critical technologies.
Innovative Aerosystems (ISSC) has emerged as a standout performer within the aerospace and avionics space, with its stock reflecting optimism around rising demand for advanced cockpit and navigation systems. Recent trading has seen shares hold near the upper end of their range, supported by strong fundamentals and a diversified customer base spanning business aviation, commercial airlines, and military platforms.
Hexcel Corporation (HXL), a leading supplier of advanced composite materials used across aerospace, defense, and industrial markets, has maintained steady momentum amid a shifting industry backdrop. Recent share performance reflects investor optimism around a gradual recovery in commercial aviation, balanced against concerns about production timing and cost pressures.
AAR Corp. shares have shown notable strength in recent trading, benefiting from favorable conditions in the aerospace and defense sector as global air travel continues to recover. The stock has trended higher on the back of strong fundamentals in parts distribution, maintenance, and engineering services.
TAT Technologies (TATT), a provider of aerospace and defense systems with a focus on heat transfer solutions and MRO services, has demonstrated notable strength in recent trading. Shares have climbed sharply over the past month, reflecting growing investor confidence in the company’s operational improvements and exposure to aerospace recovery trends.
The Utilities Select Sector SPDR Fund (XLU) has shown unusual volatility early in 2026. After a strong 22% gain through November 2025, fueled by AI-driven electricity demand and falling interest rates, XLU dipped to around $43 by January 7 amid broader equity pullbacks and insider selling at holdings like UGI Corporation. While utilities are typically stable, this behavior signals potential opportunities as data center electricity demand is projected to double by 2030, positioning utilities as key beneficiaries of the AI boom.
TSM’s upcoming earnings carry outsized importance for the semiconductor industry. As the world’s leading contract chip manufacturer, TSMC underpins AI innovation for customers such as Nvidia and Apple. Its results often serve as a bellwether for global chip demand, capacity constraints, and pricing trends.
Goldman Sachs (GS) is expected to report Q4 2025 EPS of $11.65 on revenue of $13.85 billion, reflecting steady results as investment banking activity continues to recover.